BRPI0406801B8 - derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes - Google Patents

derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Info

Publication number
BRPI0406801B8
BRPI0406801B8 BRPI0406801A BRPI0406801A BRPI0406801B8 BR PI0406801 B8 BRPI0406801 B8 BR PI0406801B8 BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 B8 BRPI0406801 B8 BR PI0406801B8
Authority
BR
Brazil
Prior art keywords
thieno
modulation
autoimmune diseases
sup
pyrimidinedione derivatives
Prior art date
Application number
BRPI0406801A
Other languages
English (en)
Portuguese (pt)
Inventor
Simon David Guile
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0406801A publication Critical patent/BRPI0406801A/pt
Publication of BRPI0406801B1 publication Critical patent/BRPI0406801B1/pt
Publication of BRPI0406801B8 publication Critical patent/BRPI0406801B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0406801A 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes BRPI0406801B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
SE0300119-5 2003-01-17
PCT/SE2004/000052 WO2004065394A1 (en) 2003-01-17 2004-01-15 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Publications (3)

Publication Number Publication Date
BRPI0406801A BRPI0406801A (pt) 2006-01-17
BRPI0406801B1 BRPI0406801B1 (pt) 2018-04-03
BRPI0406801B8 true BRPI0406801B8 (pt) 2021-05-25

Family

ID=20290154

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406801A BRPI0406801B8 (pt) 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Country Status (23)

Country Link
US (2) US7384951B2 (enExample)
EP (1) EP1587812B1 (enExample)
JP (1) JP4519121B2 (enExample)
KR (2) KR20110125256A (enExample)
CN (1) CN100334093C (enExample)
AT (1) ATE335748T1 (enExample)
AU (1) AU2004206012B2 (enExample)
BR (1) BRPI0406801B8 (enExample)
CA (1) CA2512441C (enExample)
DE (1) DE602004001857T2 (enExample)
EG (1) EG25613A (enExample)
ES (1) ES2270337T3 (enExample)
IL (1) IL169370A (enExample)
IS (1) IS2376B (enExample)
MX (1) MXPA05007496A (enExample)
NO (1) NO333702B1 (enExample)
NZ (1) NZ541217A (enExample)
PL (1) PL214682B1 (enExample)
RU (1) RU2331647C2 (enExample)
SE (1) SE0300119D0 (enExample)
UA (1) UA81788C2 (enExample)
WO (1) WO2004065394A1 (enExample)
ZA (1) ZA200505364B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
JP2006515880A (ja) * 2003-01-17 2006-06-08 アストラゼネカ・アクチエボラーグ 自己免疫疾患の調節におけるチエノピリダジノンとその使用
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
SG184766A1 (en) * 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
CN102361874A (zh) * 2009-03-23 2012-02-22 格兰马克药品股份有限公司 作为trpa1调节剂的呋喃并嘧啶二酮衍生物
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2804852A2 (en) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutic compounds
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
PT3060562T (pt) * 2013-10-21 2021-09-02 Genosco Compostos de pirimidina substituídos e sua utilização como inibidores da syk
US10329303B2 (en) 2015-01-22 2019-06-25 The Scripps Research Institute Heterocyclic inhibitors of monocarboxylate transporter
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR101730536B1 (ko) * 2016-03-17 2017-05-02 주식회사 골프존 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체
KR101712836B1 (ko) * 2016-03-17 2017-03-22 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101712838B1 (ko) * 2016-03-17 2017-03-07 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CN119080799B (zh) * 2024-09-27 2025-12-05 山东大学 一种n-羟基噻吩并嘧啶二酮类衍生物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
JP2001525413A (ja) 1997-12-05 2001-12-11 アストラゼネカ ユーケイ リミテッド 新規化合物
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ES2211161T3 (es) * 1998-08-28 2004-07-01 Astrazeneca Ab Tieno(2,3-d)pirimidindionas novedosas, procedimiento para su preparacion y uso de las mismas en terapia.
WO2001083489A1 (en) * 2000-05-04 2001-11-08 Astrazeneca Ab THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
JP2006515880A (ja) 2003-01-17 2006-06-08 アストラゼネカ・アクチエボラーグ 自己免疫疾患の調節におけるチエノピリダジノンとその使用

Also Published As

Publication number Publication date
ZA200505364B (en) 2006-09-27
CA2512441C (en) 2012-01-03
NO20053826L (no) 2005-10-17
JP2006516974A (ja) 2006-07-13
DE602004001857T2 (de) 2007-05-24
SE0300119D0 (sv) 2003-01-17
EP1587812B1 (en) 2006-08-09
JP4519121B2 (ja) 2010-08-04
KR101107486B1 (ko) 2012-01-19
CN100334093C (zh) 2007-08-29
EP1587812A1 (en) 2005-10-26
NZ541217A (en) 2008-05-30
IS7965A (is) 2005-07-29
CA2512441A1 (en) 2004-08-05
KR20050092760A (ko) 2005-09-22
DE602004001857D1 (de) 2006-09-21
US20060052400A1 (en) 2006-03-09
HK1081959A1 (en) 2006-05-26
PL378222A1 (pl) 2006-03-20
AU2004206012A1 (en) 2004-08-05
KR20110125256A (ko) 2011-11-18
US20080214579A1 (en) 2008-09-04
RU2005121494A (ru) 2006-02-10
MXPA05007496A (es) 2005-09-21
UA81788C2 (uk) 2008-02-11
WO2004065394A1 (en) 2004-08-05
RU2331647C2 (ru) 2008-08-20
IL169370A0 (en) 2007-07-04
EG25613A (en) 2012-03-22
US7384951B2 (en) 2008-06-10
IL169370A (en) 2011-05-31
AU2004206012B2 (en) 2007-06-14
BRPI0406801A (pt) 2006-01-17
NO20053826D0 (no) 2005-08-15
CN1761672A (zh) 2006-04-19
NO333702B1 (no) 2013-08-26
BRPI0406801B1 (pt) 2018-04-03
IS2376B (is) 2008-07-15
PL214682B1 (pl) 2013-09-30
ATE335748T1 (de) 2006-09-15
ES2270337T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
BRPI0406801B8 (pt) derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
PT1263725E (pt) Novos compostos
IS6658A (is) Ný efnasambönd
EA200401526A1 (ru) Новые соединения и их применение
SE9902987D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
ATE316083T1 (de) Adamantanderivate
AU2003228770A1 (en) Substituted pyrazolopyrimidines
SE0402925D0 (sv) Novel Compounds
TW200604197A (en) New compounds
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0101038D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
GB0120461D0 (en) Novel compounds
SE0401763D0 (sv) Compounds
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
ATE274515T1 (de) Pyrazolopyridinderivate
SE0302755D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
SE0403118D0 (sv) New compounds 2
MXPA05007495A (es) Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
BRPI0410026A (pt) derivados de 3-amino-croman quinolina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.